202 related articles for article (PubMed ID: 11692302)
1. Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis.
Trikalinos TA; Ioannidis JP
Clin Infect Dis; 2001 Dec; 33(11):1901-9. PubMed ID: 11692302
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
[TBL] [Abstract][Full Text] [Related]
4. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
[TBL] [Abstract][Full Text] [Related]
6. Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxis.
Eigenmann C; Flepp M; Bernasconi E; Schiffer V; Telenti A; Bucher H; Wagels T; Egger M; Furrer H;
Clin Infect Dis; 2003 Apr; 36(7):917-21. PubMed ID: 12652393
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection.
Schürmann D; Bergmann F; Albrecht H; Padberg J; Wünsche T; Grünewald T; Schürmann M; Grobusch M; Vallée M; Ruf B; Suttorp N
Eur J Clin Microbiol Infect Dis; 2002 May; 21(5):353-61. PubMed ID: 12072919
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group.
Mussini C; Pezzotti P; Antinori A; Borghi V; Monforte Ad; Govoni A; De Luca A; Ammassari A; Mongiardo N; Cerri MC; Bedini A; Beltrami C; Ursitti MA; Bini T; Cossarizza A; Esposito R;
Clin Infect Dis; 2003 Mar; 36(5):645-51. PubMed ID: 12594647
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).
El-Sadr WM; Luskin-Hawk R; Yurik TM; Walker J; Abrams D; John SL; Sherer R; Crane L; Labriola A; Caras S; Pulling C; Hafner R
Clin Infect Dis; 1999 Oct; 29(4):775-83. PubMed ID: 10589887
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia.
Madden RM; Pui CH; Hughes WT; Flynn PM; Leung W
Cancer; 2007 Apr; 109(8):1654-8. PubMed ID: 17345613
[TBL] [Abstract][Full Text] [Related]
11. A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy.
Green H; Hay P; Dunn DT; McCormack S;
HIV Med; 2004 Jul; 5(4):278-83. PubMed ID: 15236617
[TBL] [Abstract][Full Text] [Related]
12. Assessment of immune reconstitution to Pneumocystis carinii in HIV-1 patients under different highly active antiretroviral therapy regimens.
Atzori C; Clerici M; Trabattoni D; Fantoni G; Valerio A; Tronconi E; Cargnel A
J Antimicrob Chemother; 2003 Aug; 52(2):276-81. PubMed ID: 12837736
[TBL] [Abstract][Full Text] [Related]
13. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
[TBL] [Abstract][Full Text] [Related]
14. Pneumocystis carinii pneumonia in the Federal Republic of Germany in the era of changing antiretroviral therapy - IDKF 13 -. German AIDS Study Group (GASG/IdKF).
Stoehr A; Arasteh K; Staszewski S; Brockmeyer N; Albrecht H; Mertenskötter T; Jablonowski H; Emminger C; Rockstroh JK; Baumgarten R; Bogner J; Loch T; Plettenberg A
Eur J Med Res; 1999 Apr; 4(4):131-4. PubMed ID: 10205287
[TBL] [Abstract][Full Text] [Related]
15. Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection.
Hughes WT; Dankner WM; Yogev R; Huang S; Paul ME; Flores MA; Kline MW; Wei LJ;
Clin Infect Dis; 2005 Jan; 40(1):136-45. PubMed ID: 15614703
[TBL] [Abstract][Full Text] [Related]
16. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens.
Ioannidis JP; Cappelleri JC; Skolnik PR; Lau J; Sacks HS
Arch Intern Med; 1996 Jan; 156(2):177-88. PubMed ID: 8546551
[TBL] [Abstract][Full Text] [Related]
17. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
Viani RM; Araneta MR; Deville JG; Spector SA
Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy.
Schneider MM; Borleffs JC; Stolk RP; Jaspers CA; Hoepelman AI
Lancet; 1999 Jan; 353(9148):201-3. PubMed ID: 9923876
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P
Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526
[TBL] [Abstract][Full Text] [Related]
20. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997.
San-Andrés FJ; Rubio R; Castilla J; Pulido F; Palao G; de Pedro I; Costa JR; del Palacio A
Clin Infect Dis; 2003 May; 36(9):1177-85. PubMed ID: 12715314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
